Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025

Dyne Therapeutics, Inc.

Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).
Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.
Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.
Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.
Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dyne Therapeutics, Inc. reported the fourth quarter and full year 2023 results: net income Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share, EPS $1.09 per basic and diluted share.

Period: the fourth quarter and full year 2023
Net income: Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share
EPS: $1.09 per basic and diluted share
Result: reported results

Exact text from the filing

Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.

View on SEC.gov

Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-025408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.